Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting ...

Rein Therapeutics initiates RENEW phase 2 trial of LTI-03 in patients with idiopathic pulmonary fibrosis: Austin, Texas Tuesday, May 13, 2025, 18:00 Hrs [IST] Rein Therapeutics (R ...

Rein Therapeutics has begun screening and recruiting patients for its renew phase 2 trial, assessing LTI-03 as a potential ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed ...

A collaboration between Nasdaq quoted biopharma company Rein Therapeutics in Texas and Cambridge UK innovator Qureight Ltd ...

Qureight’s cloud-based, vendor-agnostic Core Imaging Platform is GDPR, HIPPA and NHS Digital compliant. The platform has ...

The Phase II trial will assess the therapy’s safety, tolerability and its activity across various biomarkers in IPF patients.

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...